age1

Backing contrarian founders building breakthrough longevity companies to increase healthy lifespan | @AlexJColville @LauraDeming

[Celine Halioua @celinehalioua]

nice piece about our work in the atlantic this morning :)

[Laura 🌲 ⛰️ @LauraDeming]

first FDA approval resulting from a company in the portfolio!

so so excited for all those involved + the patients who now have access to a transformative therapy ❤️

[Fynn Comerford @FynnComerford]

@Dhruv_Sumathi and I made something :)

we’ve been filming the beauty of organ preservation research at @untillabs for a while now. it’s not an explainer or company video, it’s a window into how it feels to work on this problem from the inside.

[60 Minutes @60Minutes]

A biotech startup is conducting a clinical trial on a daily beef-flavored pill designed to help dogs live healthier, longer lives, says Celine Halioua, founder of Loyal. https://t.co/mo1X1AFxRd

[Alex Colville @AlexJColville]

Update: @vkhosla is joining us for a fireside chat at the AI x Longevity Summit in San Francisco.

We'll host an AI lab panel feat leaders from Google DeepMind, OpenAI, Anthropic, + lightning talks (incl from @MartinBJensen) on how AI can actually move the needle on longevity.

[Alex Colville @AlexJColville]

AGI timelines are accelerating dramatically. The promise of many working in the field is the ultimate health impact to humanity including cures to cancer and significantly increasing healthy lifespan. But how? Join the first Summit on the Convergence of AI and Longevity!

[Satvik Dasariraju @satvik_93]

Coming off of last week where we announced we @age1vc led Loyal's $100M Series C and co-led Aerska's $39M Series A, we're thinking a lot about what areas we want to invest in next. 🧵

[Celine Halioua @celinehalioua]

Loyal has raised a $100M Series C from age1, Baillie Gifford, existing investors, & more

this brings Loyal's total funding to over a quarter of a billion dollars

we are building the longevity pharma, starting with dog longevity. thanks @FastCompany for the exclusive ->

[Alex Colville @AlexJColville]

Stoked to reveal the news! We led Loyal’s $100M Series C. Why?

Because
1) @celinehalioua is one of the most special humans and gifted founders you will ever meet.
2) Dogs and humans deserve aging drugs!! Her team’s 1st approved therapies are going to change forever how we age!!

[Alex Colville @AlexJColville]

Very happy to share that we co-led Aerska's $39M Series A with @eqt's Dementia Fund! Neurodegeneration has robbed us of too much. Time to fight back!! $60M to date for Aerska by @Jack_O_Meara in just a couple months over one year of existing! We movin.

[Matthew Herper @matthewherper]

Biotech doubles financing in quest to silence genes behind neurological diseases https://t.co/4cYeKe4sAH via @statnews

[age1 @age1vc]

One of the key reasons why we don't have more cures and disease modifying therapies is that we are not great at find successful novel drug targets. @LynettaWang126 is on the chase to break down in a new series how to find better targets to accelerate more cures!!

[Lynetta Wang @LynettaWang126]

“Biology is hard”, betting on it is harder.

Launching the first piece of a 5-part series for founders & scientists trying to find “the” successful target: https://t.co/7BtoCqQO4a

Big thanks to @age1vc crew - genuinely fun building this:)

[Andrew Reed @andrew__reed]

Taking this pill so I never lose that dog in me

[Ashlee Vance @ashleevance]

Scoop this mornin on General Control and @ladanuzhna and their attempts to rewire the human genome

Full story in the comments

[Satvik Dasariraju @satvik_93]

Thrilled for this glimpse into what Lada and team have been building over the last 2 years!

General Control is being built with a high ambition matched only by the team’s meticulousness and sharp attention to optimizing the positioning of epigenetic editing for the most pressing therapeutic opportunities of today and tomorrow. Aiming at multifactorial, population-scale diseases of aging, General Control is advancing epigenetic editing medicines to precisely tune up or down expression of single or multiple factors. Such a method will break through the limitations of current therapeutic modalities, the majority of which can only downregulate a single target.

No better team to pursue this vision than the inimitably relentless founder @ladanuzhna, head of research and epigenetic editing extraordinaire @gcarosso, and the stellar early team being assembled. LFG ⚡️

[lada @ladanuzhna]

I am excited to announce what I’ve been working on for the past 2 years. General Control is a mandate to develop programmable therapies that make durable, reversible adjustments to gene expression - epigenetically activating or silencing multiple targets at once. In the past 16 months, we:
- Achieved a technical leap in epigenetic editing by engineering an editor library that outperforms leading published systems on potency and durability
- Launched a multi-target partnership with Novo Nordisk
- Generated animal data for 3 different programs and developed a lead we are now ready to translate to the clinic
- Raised 5.5M pre-seed from @age1vc @fiftyyears @tmrohan @mollyfmielke and others

[lada @ladanuzhna]

Always a blast talking about bio with @ElliotHershberg and @JorgeCondeBio

[Celine Halioua @celinehalioua]

absolutely none of this matters relative to getting our first drug approved

but i am proud that dog longevity & loyal have gone from literally laugh-in-my-face

to (relatively) consensus?

build the future you want to see :) thnx @Forbes @TrueBridgeCP

[TBPN @tbpn]

Why do bigger dogs have shorter lifespans?

@celinehalioua, founder and CEO of dog longevity company @loyalfordogs, explains how understanding why is key to treatments that help them live longer.

[Endpoints News @endpts]

After Ochre Bio, Jack O’Meara is back with Aerska — a neuro-focused biotech that just raised $21M to speed siRNAs into the clinic. https://t.co/jsyYDYs8fl